Brexpiprazole (OPC-34712)

DRUG2 trials

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.

Conditions

Schizophrenia

Phase 1

Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia

CompletedNCT02411695

Otsuka Pharmaceutical Development & Commercialization, Inc.Schizophrenia

Start: 2015-03-01End: 2017-01-01Updated: 2026-04-28

Phase 3

Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia

CompletedNCT03198078

Otsuka Pharmaceutical Development & Commercialization, Inc.Schizophrenia

Start: 2017-06-30End: 2023-04-03Updated: 2023-12-20

Related Papers

Efficacy and safety of brexpiprazole in adolescents with schizophrenia: a multicountry, randomised, double-blind, placebo-controlled, phase 3 trial with an active reference.

2025-04-074 citations

Efficacy and safety of brexpiprazole in early-episode schizophrenia: post hoc analysis of clinical trials in adults and adolescents

European Psychiatry2025-04-01

Safety and Tolerability of Brexpiprazole in Adolescents With Schizophrenia: A Long-Term, Open-Label Study

JAACAP Open2024-05-267 citations